United Therapeutics valuation
Valuation
The P/E ratio is 22.2. The average price target of 14 analysts is $687.14.
Data as of November 17, 2026
United Therapeutics compared with similar companies
United Therapeutics's P/E (trailing 12 months): 22.2, −20% against the median of a group of 9 similar companies (27.6).
| Metric | United Therapeutics | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 22.2 | 27.6 | 22.2 – 78.9 | Middle |
| Forward P/E | 17.0 | 20.9 | 14.4 – 40.1 | Middle |
| EV/EBITDA | 17.0 | 17.0 | 14.2 – 33.0 | Middle |
| Price/book | 3.97 | 7.94 | 4.38 – 11.3 | Low |
| Price/sales | 7.85 | 6.19 | 3.74 – 12.1 | Middle |
| Gross margin | 86.3% | 73.8% | 64.7% – 85.2% | High |
| Operating margin | 39.4% | 32.8% | 23.3% – 37.8% | High |
| Net margin | 38.6% | 27.0% | 13.9% – 37.6% | High |
| ROE | 19.1% | 19.3% | 15.3% – 20.3% | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
United Therapeutics: valuation over time
On the latest fiscal year's earnings (2025), United Therapeutics's P/E today is 20.8, above the median of its last 9 fiscal years (14.3; between 8.13 and 21.5 from 2016 to 2025). Relative to earnings, the stock costs more than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $487.25 | $27.86 | 17.5 |
| 2024 | $352.84 | $24.64 | 14.3 |
| 2023 | $219.89 | $19.81 | 11.1 |
| 2022 | $278.09 | $15.00 | 18.5 |
| 2021 | $216.08 | $10.06 | 21.5 |
| 2020 | $151.79 | $11.54 | 13.2 |
| 2019 | $88.08 | -$2.39 | — |
| 2018 | $108.90 | $13.39 | 8.13 |
| 2017 | $147.95 | $9.31 | 15.9 |
| 2016 | $143.43 | $15.25 | 9.41 |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $25.04B
- Enterprise value
- $22.97B
- PEG
- 2.22
- EV/revenue
- 7.21
Profitability and growth
- ROA
- 10.9%
- Revenue growth (year over year)
- 4.1%
- Earnings growth (year over year)
- -20.3%
Financial health
- Total cash
- $2.07B
- Total debt
- $0
- Current ratio
- 4.61
- Quick ratio
- 3.87
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $687.14
- Median price target
- $711.50
- High price target
- $850.00
- Low price target
- $390.00
- Analysts with a price target
- 14
- Consensus
- Buy
- Forward EPS
- $34.62
- EPS estimate, current year
- $24.96
Shares and trading
- Beta
- 0.48
- Average volume
- 703.57K
- Shares outstanding
- 42.59M
- Float
- 38.91M
- Institutional ownership
- 102.1%
- Insider ownership
- 2.5%
- Short interest (% of float)
- 5.0%
- Short ratio (days)
- 2.12
